News Release 

Altered lipid metabolism following childbirth predicts later diabetes risk

Measuring postpartum changes in lipid metabolism in women who had gestational diabetes may identify those at risk of developing type 2 diabetes and enable them to receive preventive care

eLife

Scientists have found that disruptions to the metabolism of lipids occur after childbirth in women with gestational diabetes who go on to develop type 2 diabetes.

Their results, published today in eLife, suggest that specific lipids - molecules that make up the building blocks of living cells, store energy and can serve as cellular messengers - could help to predict the progression from gestational to type 2 diabetes in women who have just given birth. The findings may one day help physicians identify those at risk of developing type 2 diabetes after a pregnancy and ensure they receive preventive care.

Gestational diabetes is a complication that affects between 1-14% of pregnant women. It occurs when a pregnant woman is unable to produce enough of a hormone called insulin and, if untreated, can lead to dangerously high blood sugar. While most women recover after childbirth, more than a third will develop type 2 diabetes within 10 years, but scientists do not yet understand why. "It is critical to uncover the underlying metabolic changes that cause women to develop type 2 diabetes so that we can identify and start preventing more of these cases," says lead author Mi Lai, Postdoctoral Research Fellow at the University of Toronto, Canada.

To do this, Lai and her colleagues analysed more than 1,000 different lipids found in fasting blood plasma samples collected from 350 women with gestational diabetes between six to nine weeks after their delivery. Of these women, 171 went on to develop type 2 diabetes within the next eight years and 179 did not. The analysis identified 311 lipids associated with a higher risk of developing diabetes and 70 associated with a lower risk.

The team found that dyslipidemia after childbirth, where an abnormal amount of lipids occur in the blood, is enabled by an increase in the metabolism of glycerolipid - which activates lipid storage in the body - and the suppression of two other types of lipid called phospholipids and sphingolipids.

"There appears to be an increase in the formation of fat prior to the onset of type 2 diabetes," explains co-senior author Feihan Dai, a research scientist of physiology at the University of Toronto. "This process shifts metabolites towards triacylglycerol formation and away from phospholipids and sphingolipids, and this might be the driving force of the onset of the disease."

Additionally, the team showed that testing women for changes in a set of 11 lipids could help predict which women would go on to develop type 2 diabetes. Combining this lipid panel with two routine postpartum tests for blood sugar levels was even more effective at identifying which women would develop the condition.

"Our findings lay the groundwork for further research and possible development of new methods to help predict the progression from gestational diabetes to type 2 diabetes in women following childbirth," concludes co-senior author Michael Wheeler, Professor of Physiology and Medicine at the University of Toronto. "Predicting this risk early would allow for the timely intervention and prevention of diabetes in new mothers."

###

Reference

The paper 'Underlying dyslipidemia postpartum in women with a recent GDM pregnancy who develop type 2 diabetes' can be freely accessed online at https://doi.org/10.7554/eLife.59153. Contents, including text, figures and data, are free to reuse under a CC BY 4.0 license.

Media contact

Emily Packer, Senior Press Officer

eLife

e.packer@elifesciences.org

01223 855373

About eLife

eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We work across three major areas: publishing, technology and research culture. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Human Biology and Medicine, while exploring creative new ways to improve how research is assessed and published. We also invest in open-source technology innovation to modernise the infrastructure for science publishing and improve online tools for sharing, using and interacting with new results. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.

To read the latest Human Biology and Medicine research published in eLife, visit https://elifesciences.org/subjects/human-biology-medicine.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.